1h-imidazo(4,5-b)pyridine has been researched along with Pancreatic Neoplasms in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Damghani, T; Edraki, N; Firuzi, O; Kayani, Z; Khoshneviszadeh, M; Moosavi, F; Mortazavi, M; Pirhadi, S; Saso, L | 1 |
1 other study(ies) available for 1h-imidazo(4,5-b)pyridine and Pancreatic Neoplasms
| Article | Year |
|---|---|
Imidazopyridine hydrazone derivatives exert antiproliferative effect on lung and pancreatic cancer cells and potentially inhibit receptor tyrosine kinases including c-Met.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Flow Cytometry; fms-Like Tyrosine Kinase 3; Gene Expression Regulation, Neoplastic; Humans; Hydrazones; Imidazoles; Lung Neoplasms; Molecular Docking Simulation; Molecular Dynamics Simulation; Pancreatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyridines; Receptor Protein-Tyrosine Kinases; Receptor, Platelet-Derived Growth Factor alpha; Structure-Activity Relationship | 2021 |